目的:探讨伴有FMS样酪氨酸激酶3-内部串联重复突变(FLT3-ITD)急性髓系白血病(AML)的临床特点和对治疗的反应。方法:回顾性分析从2014年1月到2017年7月初诊AML(除M3型)128例,分为FLT3-ITD突变和无FLT3-ITD突变组。FLT3-ITD和NPM1突变采用...目的:探讨伴有FMS样酪氨酸激酶3-内部串联重复突变(FLT3-ITD)急性髓系白血病(AML)的临床特点和对治疗的反应。方法:回顾性分析从2014年1月到2017年7月初诊AML(除M3型)128例,分为FLT3-ITD突变和无FLT3-ITD突变组。FLT3-ITD和NPM1突变采用PCR和基因测序法检测。采用标准3+7方案或CAG作为首次诱导化疗方案。4人接受索拉非尼治疗。总生存期(OS)定义为从确诊到死亡或最后随访之间的持续时间。统计采用SPSS 17.0软件,总体生存(overall survival,OS)采用Kaplan Meier方法计算。结果:有临床资料可评价97例,4例FLT3-TKD突变(占4.1%),19例FLT3-ITD突变(占19.59%)。中位白细胞计数(WBC)、外周血幼稚细胞比例和乳酸脱氢酶(LDH)值在FLT3-ITD组明显升高,在FLT3-ITD突变组和无突变组分别为64.65(1.07-587.92)×109/L vs 39.68(0.45-203.81)×109/L(P=0.00)、69.62(16-99)%vs 36.35(0-92)%(P=0.00)和LDH 526(124-2729)U/L vs 265(20-1977)U/L(P=0.029)。同时合并NPM1突变的比率在FLT3-ITD组和无FLT3-ITD组分别为36.8%(7/19)和6.8%(5/74)(P=0.002)。CR+PR在FLT3-ITD组低于无突变组[31.6%(6/19)vs 64.9%(48/74)](P=0.028)。OS时间在FLT3-ITD组较无突变组明显缩短,分别为5和18个月(P=0.027)。OS在FLT3-ITD和NPM1双阳性患者与FLT3-ITD单阳性患者间无差异,均为5个月(P=0.880)。接受索拉非尼治疗的患者中位OS时间为13个月。结论:FLT3-ITD是AM L中的常见突变,FLT3-ITD AM L更易并发NPM1基因突变,表现有更高的白细胞数和外周血原始细胞及LDH水平,其首次治疗后的CR率低,总体生存差。展开更多
目的:分析急性髓细胞白血病(AML)患者中fms样酪氨酸激酶3(FLT3)基因的内部串联重复(internal tandem duplication,ITD)突变的发生率,以及该突变对患者的血常规水平、免疫表型、完全缓解(CR)率和总生存时间的影响。探讨FLT3ITD(+)AML患...目的:分析急性髓细胞白血病(AML)患者中fms样酪氨酸激酶3(FLT3)基因的内部串联重复(internal tandem duplication,ITD)突变的发生率,以及该突变对患者的血常规水平、免疫表型、完全缓解(CR)率和总生存时间的影响。探讨FLT3ITD(+)AML患者服用索拉菲尼对中位生存时间的影响。方法:采用PCR方法检测130例初诊急性髓细胞白血病患者骨髓中FLT3-ITD的表达,用Kaplan-Meier生存曲线分析AML的预后。结果:130例初发AML患者中检出FLT3-ITD(+)患者共23例(17.7%)。FLT3-ITD(+)患者发病时白细胞高、骨髓原始细胞比例高(P<0.05),FLT3-ITD(+)对AML(除外APL)患者的CR率、OS时间均有不良影响(P<0.05)。索拉菲尼联合化疗的FLT3-ITD(+)患者的中位生存时间有所延长(12个月,未口服则为7个月)。结论:FLT3-ITD突变是AML患者中常见的基因突变类型,FLT3-ITD(+)降低患者的CR率,缩短OS。索拉菲尼可作为FLT3-ITD(+)急性髓细胞白血病患者的治疗选择。展开更多
本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采...本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采用聚合酶链式反应检测NPM1及FLT3-ITD突变状态。结果表明,与无NPM1突变患者相比,突变者初诊时外周血白细胞数较多(30.7×109/L vs 8.6×109/L,P=0.002);FLT3-ITD突变患者较无突变患者具有更多的外周血白细胞数(42.38×109/L vs 11.45×109/L,P=0.033)及更高的骨髓原始细胞百分比(74.0%vs 60.25%,P=0.036)。外周血白细胞数及骨髓原始细胞百分比在NPM1、FLT3-ITD无突变组、单独NPM1突变组、单独FLT3-ITD突变组到NPM1、FLT3-ITD双突变组逐步升高(均P<0.05)。白细胞数大于12.55×109/L的患者NPM1突变率明显升高(P=0.002),大于37.85×109/L者FLT3-ITD突变率明显升高(P=0.033);原始细胞比例大于72.25%的FLT3-ITD突变率明显升高(P=0.008)。NPM1突变患者首疗程完全缓解率(CR)明显高于无突变者(78.13%vs 40.0%,χ2=4.651,P=0.031)。结论:NPM1及FLT3-ITD突变患者白细胞计数及原始细胞比例大,提示NPM1与FLT3-ITD突变均可能促进白血病细胞增殖,且二者可能具有协同效应。展开更多
Mutations of fins-like tyrosine kinase 3 （FLT3） and nucleophosmin （NPM1） exon 12 genes are the most common abnormalities in adult acute myeloid leukemia （AML） with normal cytogenetics. To assess the prognostic i...Mutations of fins-like tyrosine kinase 3 （FLT3） and nucleophosmin （NPM1） exon 12 genes are the most common abnormalities in adult acute myeloid leukemia （AML） with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction （PCR） and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication （FLT3/ITD） and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 （19.7%） of 76 subjects, and NPM1 mutation in 20 （26.3%） subjects. Seven （9.2%） cases were positive for both FLT3/ITD and NPM1 mutations Significantly more FLT3/ITD aberration was detected in subjects with French-American-British （FAB） M1 （42.8%）. NPM1 mutation was frequently detected in subjects with M5 （47.1%） and infrequently in subjects with M2 （11.1%）. FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITD- positive group had a lower complete remission （CR） rate （53.3% vs. 83.6%）. Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival （OS） and relapse-free survival （RFS）. The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group （P=0.069）. Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.展开更多
Summary： Patients with FLT3-ITD^mmutt/NPM1- cytogenetically normal acute myeloid leukemia （CN-AML）, as high-risk molecular group in CN-AML, are associated with a worse prognosis than other CN-AML patients. It is be...Summary： Patients with FLT3-ITD^mmutt/NPM1- cytogenetically normal acute myeloid leukemia （CN-AML）, as high-risk molecular group in CN-AML, are associated with a worse prognosis than other CN-AML patients. It is beneficial to generate xenotransplantation model of FLT3-ITD^mut/NPM1- CN-AML to better understand the pathogenesis and therapeutic strategies of such AML subtype. The purpose of present study was to establish the xenotransplantation model in NOD/SCID mice with FLT3-ITD^mut/NPM1- CN-AML primary cells. The FLT3-ITD^mut/NPM1- CN-AML primary cells from 3 of 7 cases were successfully transplanted into NOD/SCID mice, and human CD45 positive cells were detected in the peripheral blood, spleen and bone marrow of mice by using flow cytometry. Infiltration of human leukemia cells in various organs of mice was observed by using immunohistochemistry. Gene analysis confirmed sustained FLT3/ITD mutation without NPM1 mutation in mice. By performing serial transplantation, it was found that characteristics of the leukemia cells in secondary and tertiary genera- tion models remained unchanged. Moreover, in vivo cytarabine administration could extend survival of NOD/SCID mice, which was consistent with clinical observation. In conclusion, we successfully estab- lished xenotransplantation model of human FLT3-ITD^mut/NPM1- CN-AML in NOD/SCID mice. The model was able to present primary disease and suitable to evaluate the curative effects of new drugs or therapy strategies.展开更多
文摘目的:探讨伴有FMS样酪氨酸激酶3-内部串联重复突变(FLT3-ITD)急性髓系白血病(AML)的临床特点和对治疗的反应。方法:回顾性分析从2014年1月到2017年7月初诊AML(除M3型)128例,分为FLT3-ITD突变和无FLT3-ITD突变组。FLT3-ITD和NPM1突变采用PCR和基因测序法检测。采用标准3+7方案或CAG作为首次诱导化疗方案。4人接受索拉非尼治疗。总生存期(OS)定义为从确诊到死亡或最后随访之间的持续时间。统计采用SPSS 17.0软件,总体生存(overall survival,OS)采用Kaplan Meier方法计算。结果:有临床资料可评价97例,4例FLT3-TKD突变(占4.1%),19例FLT3-ITD突变(占19.59%)。中位白细胞计数(WBC)、外周血幼稚细胞比例和乳酸脱氢酶(LDH)值在FLT3-ITD组明显升高,在FLT3-ITD突变组和无突变组分别为64.65(1.07-587.92)×109/L vs 39.68(0.45-203.81)×109/L(P=0.00)、69.62(16-99)%vs 36.35(0-92)%(P=0.00)和LDH 526(124-2729)U/L vs 265(20-1977)U/L(P=0.029)。同时合并NPM1突变的比率在FLT3-ITD组和无FLT3-ITD组分别为36.8%(7/19)和6.8%(5/74)(P=0.002)。CR+PR在FLT3-ITD组低于无突变组[31.6%(6/19)vs 64.9%(48/74)](P=0.028)。OS时间在FLT3-ITD组较无突变组明显缩短,分别为5和18个月(P=0.027)。OS在FLT3-ITD和NPM1双阳性患者与FLT3-ITD单阳性患者间无差异,均为5个月(P=0.880)。接受索拉非尼治疗的患者中位OS时间为13个月。结论:FLT3-ITD是AM L中的常见突变,FLT3-ITD AM L更易并发NPM1基因突变,表现有更高的白细胞数和外周血原始细胞及LDH水平,其首次治疗后的CR率低,总体生存差。
文摘目的:分析急性髓细胞白血病(AML)患者中fms样酪氨酸激酶3(FLT3)基因的内部串联重复(internal tandem duplication,ITD)突变的发生率,以及该突变对患者的血常规水平、免疫表型、完全缓解(CR)率和总生存时间的影响。探讨FLT3ITD(+)AML患者服用索拉菲尼对中位生存时间的影响。方法:采用PCR方法检测130例初诊急性髓细胞白血病患者骨髓中FLT3-ITD的表达,用Kaplan-Meier生存曲线分析AML的预后。结果:130例初发AML患者中检出FLT3-ITD(+)患者共23例(17.7%)。FLT3-ITD(+)患者发病时白细胞高、骨髓原始细胞比例高(P<0.05),FLT3-ITD(+)对AML(除外APL)患者的CR率、OS时间均有不良影响(P<0.05)。索拉菲尼联合化疗的FLT3-ITD(+)患者的中位生存时间有所延长(12个月,未口服则为7个月)。结论:FLT3-ITD突变是AML患者中常见的基因突变类型,FLT3-ITD(+)降低患者的CR率,缩短OS。索拉菲尼可作为FLT3-ITD(+)急性髓细胞白血病患者的治疗选择。
文摘本研究旨在分析NPM1和FLT3-ITD突变与急性髓系白血病患者外周血白细胞数及骨髓原始细胞百分比的相关性。回顾分析我中心2009年1月至2011年12月份初治正常核型急性髓系白血病患者51例,其中男性22例,女性29例,中位年龄47岁(14-83岁)。采用聚合酶链式反应检测NPM1及FLT3-ITD突变状态。结果表明,与无NPM1突变患者相比,突变者初诊时外周血白细胞数较多(30.7×109/L vs 8.6×109/L,P=0.002);FLT3-ITD突变患者较无突变患者具有更多的外周血白细胞数(42.38×109/L vs 11.45×109/L,P=0.033)及更高的骨髓原始细胞百分比(74.0%vs 60.25%,P=0.036)。外周血白细胞数及骨髓原始细胞百分比在NPM1、FLT3-ITD无突变组、单独NPM1突变组、单独FLT3-ITD突变组到NPM1、FLT3-ITD双突变组逐步升高(均P<0.05)。白细胞数大于12.55×109/L的患者NPM1突变率明显升高(P=0.002),大于37.85×109/L者FLT3-ITD突变率明显升高(P=0.033);原始细胞比例大于72.25%的FLT3-ITD突变率明显升高(P=0.008)。NPM1突变患者首疗程完全缓解率(CR)明显高于无突变者(78.13%vs 40.0%,χ2=4.651,P=0.031)。结论:NPM1及FLT3-ITD突变患者白细胞计数及原始细胞比例大,提示NPM1与FLT3-ITD突变均可能促进白血病细胞增殖,且二者可能具有协同效应。
文摘Mutations of fins-like tyrosine kinase 3 （FLT3） and nucleophosmin （NPM1） exon 12 genes are the most common abnormalities in adult acute myeloid leukemia （AML） with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction （PCR） and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication （FLT3/ITD） and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 （19.7%） of 76 subjects, and NPM1 mutation in 20 （26.3%） subjects. Seven （9.2%） cases were positive for both FLT3/ITD and NPM1 mutations Significantly more FLT3/ITD aberration was detected in subjects with French-American-British （FAB） M1 （42.8%）. NPM1 mutation was frequently detected in subjects with M5 （47.1%） and infrequently in subjects with M2 （11.1%）. FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITD- positive group had a lower complete remission （CR） rate （53.3% vs. 83.6%）. Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival （OS） and relapse-free survival （RFS）. The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group （P=0.069）. Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.
基金supported by the National Natural Science Foundation of China (No. 81200380)
文摘Summary： Patients with FLT3-ITD^mmutt/NPM1- cytogenetically normal acute myeloid leukemia （CN-AML）, as high-risk molecular group in CN-AML, are associated with a worse prognosis than other CN-AML patients. It is beneficial to generate xenotransplantation model of FLT3-ITD^mut/NPM1- CN-AML to better understand the pathogenesis and therapeutic strategies of such AML subtype. The purpose of present study was to establish the xenotransplantation model in NOD/SCID mice with FLT3-ITD^mut/NPM1- CN-AML primary cells. The FLT3-ITD^mut/NPM1- CN-AML primary cells from 3 of 7 cases were successfully transplanted into NOD/SCID mice, and human CD45 positive cells were detected in the peripheral blood, spleen and bone marrow of mice by using flow cytometry. Infiltration of human leukemia cells in various organs of mice was observed by using immunohistochemistry. Gene analysis confirmed sustained FLT3/ITD mutation without NPM1 mutation in mice. By performing serial transplantation, it was found that characteristics of the leukemia cells in secondary and tertiary genera- tion models remained unchanged. Moreover, in vivo cytarabine administration could extend survival of NOD/SCID mice, which was consistent with clinical observation. In conclusion, we successfully estab- lished xenotransplantation model of human FLT3-ITD^mut/NPM1- CN-AML in NOD/SCID mice. The model was able to present primary disease and suitable to evaluate the curative effects of new drugs or therapy strategies.
